ValuEngine downgraded shares of The Medicines (NASDAQ:MDCO) from a buy rating to a hold rating in a report released on Monday morning.

MDCO has been the topic of several other research reports. Oppenheimer set a $50.00 price objective on shares of The Medicines and gave the stock a buy rating in a research note on Monday. Citigroup lifted their price objective on shares of The Medicines from $40.00 to $50.00 and gave the stock a buy rating in a research note on Monday, August 20th. BidaskClub raised shares of The Medicines from a hold rating to a buy rating in a research note on Tuesday, June 12th. B. Riley initiated coverage on shares of The Medicines in a report on Thursday, June 7th. They issued a buy rating and a $55.00 target price for the company. Finally, Zacks Investment Research upgraded shares of The Medicines from a hold rating to a buy rating and set a $44.00 target price for the company in a report on Tuesday, August 7th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. The stock has a consensus rating of Buy and an average price target of $52.63.

Shares of MDCO opened at $32.83 on Monday. The company has a current ratio of 2.60, a quick ratio of 2.55 and a debt-to-equity ratio of 31.23. The Medicines has a 12-month low of $24.45 and a 12-month high of $41.57.

The Medicines (NASDAQ:MDCO) last announced its quarterly earnings data on Wednesday, August 1st. The company reported ($0.70) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.00) by $0.30. The company had revenue of $1.67 million for the quarter, compared to analysts’ expectations of $7.20 million. The Medicines had a negative net margin of 668.93% and a negative return on equity of 394.33%. The business’s revenue was down 84.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.72) EPS. research analysts predict that The Medicines will post -2.52 earnings per share for the current fiscal year.

In other The Medicines news, CEO Clive Meanwell sold 50,000 shares of the firm’s stock in a transaction dated Monday, July 2nd. The shares were sold at an average price of $36.07, for a total value of $1,803,500.00. Following the completion of the transaction, the chief executive officer now directly owns 402,034 shares in the company, valued at $14,501,366.38. The sale was disclosed in a filing with the SEC, which is accessible through this link. Over the last quarter, insiders sold 150,000 shares of company stock valued at $5,731,000. Corporate insiders own 10.29% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the business. OppenheimerFunds Inc. boosted its holdings in shares of The Medicines by 0.3% during the second quarter. OppenheimerFunds Inc. now owns 707,160 shares of the company’s stock worth $25,953,000 after purchasing an additional 1,777 shares during the period. State of Wisconsin Investment Board boosted its holdings in shares of The Medicines by 2.6% during the second quarter. State of Wisconsin Investment Board now owns 70,100 shares of the company’s stock worth $2,573,000 after purchasing an additional 1,800 shares during the period. Profund Advisors LLC boosted its holdings in shares of The Medicines by 15.8% during the first quarter. Profund Advisors LLC now owns 14,146 shares of the company’s stock worth $466,000 after purchasing an additional 1,932 shares during the period. Aperio Group LLC boosted its holdings in shares of The Medicines by 8.5% during the second quarter. Aperio Group LLC now owns 28,013 shares of the company’s stock worth $1,028,000 after purchasing an additional 2,203 shares during the period. Finally, Xact Kapitalforvaltning AB boosted its holdings in shares of The Medicines by 28.9% during the first quarter. Xact Kapitalforvaltning AB now owns 10,260 shares of the company’s stock worth $338,000 after purchasing an additional 2,300 shares during the period.

The Medicines Company Profile

The Medicines Company, a biopharmaceutical company, provides medicines to treat acute and intensive care patients. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for patients undergoing percutaneous coronary intervention in the United States.

Featured Article: Trading Strategy

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for The Medicines (NASDAQ:MDCO)

Receive News & Ratings for The Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines and related companies with MarketBeat.com's FREE daily email newsletter.